Skip to main content

Table 1 Demographics and baseline characteristics of participants in both groups

From: SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial

Variables

Intervention group

(DOT + SMS) n = 137

Control group

(DOT) n = 142

Gender: n (%)

 Male

86 (62.8)

79 (55.6)

 Female

51 (37.2)

63 (44.4)

Age (years): n (%)

 18–25

22 (16.1)

34 (23.9)

 26–40

84 (61.3)

79 (55,7)

 41–55

26 (18.9)

20 (14,1)

 56–80

5 (3.7)

9 (6,3)

Level of Education: n (%)

 None

7 (5.2)

4 (2.9)

 Nusery/primary

38 (27.9)

34 (23.9)

 Secondary

69 (50.1)

74 (52.1

 Tertiary

23 (16.8)

30 (21.1)

Marital Status: n (%)

 Single

84 (61.3)

93 (65.5)

 Married

40 (29.1)

37 (26.0)

 Cohabitation

11 (8.0)

7 (5.0)

 Widower

1 (0.8)

5 (3.5)

 Divorced

1 (0.8)

0 (0.0)

Social Category: n (%)

 Student

21 (15.3)

25 (17.6)

 Working in public sector

7 (5.1)

14 (9.8)

 Working in formal private sector

20 (14.6)

15 (10.6)

 Working in informal private sector

41 (30.0)

37 (26.0)

 No work

48 (35.0)

51 (36.0)

Monthly Income (XAF): n (%)

  < 50,000

40 (29.2)

31 (21.8)

 50,000–149,000

20 (14.6)

25 (17.6)

  > 149,000

5 (3.7)

3 (2.1)

 Not reported (missing)

72 (52.5)

83 (58.5)

HIV Status: n (%)

 Negative

85 (62.0)

98 (69.0)

 Positive

27 (19.7)

12 (8.5)

 Unknown

25 (18.3)

32 (22.5)

Patient on ART (yes): n (%)

10 (7.3)

7 (4.9)

Microscopy (positive): n (%)

137 (100)

142 (100)

Treatment plan (2RHEZ/4RH): n (%)

137 (100)

142 (100)

Duration of treatment (months):

Mean (SD) / Median (Q1-Q3)

6.6 (1.2) /

6.2 (6.0–6.7)

6.5 (1.3) /

6.1 (6.0–6.6)

  1. DOT directly observed treatment, SMS short message service, 1 US Dollar 599 XAF (F CFA, currency used in Cameroon), HIV human immunodeficiency virus, ART anti-retroviral therapy, 2RHEZ/4RH 2 months of rifampicin, isoniazid, ethambutol, pyrazinamide and 4 months of rifampicin and isoniazid, SD standard deviation, Q1 first quartile, Q3 third quartile